Abstract: The present invention generally relates to method for preparing a biological sample for use in an immunolabeling process. The invention also relates to corresponding kits for use in the immunolabeling process.
Abstract: Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals.
Type:
Grant
Filed:
March 24, 2017
Date of Patent:
January 30, 2024
Assignees:
AMBERGEN, INC., MASSACHUSETTS GENERAL HOSPITAL
Inventors:
Mark J. Lim, Heather P. Ostendorff, Kenneth J. Rothschild, Donald B. Bloch
Abstract: Methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to specific oligonucleotide antibody reactivities useful in diagnosing SLE in a subject.
Type:
Grant
Filed:
January 24, 2020
Date of Patent:
December 19, 2023
Assignee:
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventors:
Irun R. Cohen, Eytan Domany, Noam Shental, Ittai Fattal
Abstract: Indirect ELISAs to detect exposure to Felis catus gammaherpesvirus 1 (FcaGHV1) in domestic cats. These ELISAs detect feline serum antibodies to ORF52 and ORF38 of FcaGHV1. The ELISA assays are sensitive, specific, and adaptable for scale up use in high throughput diagnostics.
Type:
Grant
Filed:
July 19, 2018
Date of Patent:
November 21, 2023
Assignee:
Colorado State University Research Foundation
Inventors:
Susan VandeWoude, Kathryn R. Stutzman-Rodriguez, Ryan M. Troyer
Abstract: The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixture including a sample with an antibody linked immuno-sedimentation agent and red blood cells under conditions sufficient to form red blood cell rouleaux and allow antibody-antigen binding.
Abstract: The present inventors have surprisingly found that a deoxyhypusine synthase (DHPS) gene, which was previously reported to correlate with prostate cancer and cervical cancer, is highly responsive to arteriosclerosis or digestive system cancer, whereby the gene can be used as a desired marker for arteriosclerosis or digestive system cancer. The present invention has been accomplished on the basis of this finding. Specifically, the present invention provides a method for determining arteriosclerosis or digestive system cancer, which method includes detecting expression of a deoxyhypusine synthase gene in a test sample (preferably a blood sample), and determining arteriosclerosis or digestive system cancer of a test subject from which the test sample has been obtained, on the basis of an increase in the gene expression as an index.
Type:
Grant
Filed:
November 5, 2015
Date of Patent:
October 10, 2023
Assignees:
FUJIKURA KASEI CO., LTD., National University Corporation Chiba University
Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.
Type:
Grant
Filed:
March 27, 2015
Date of Patent:
September 19, 2023
Assignee:
OPKO Diagnostics, LLC
Inventors:
Vincent Linder, David Steinmiller, Kim Pettersson, Timo Lovgren, Hans Lilja, Andrew J. Vickers, Peter T. Scardino
Abstract: Disclosed herein are methods and reagents for determining immunoglobulin gamma (IgG) antibody isotype concentration from biological samples, and for analyzing a plurality of cell samples for IgG antibody production.
Type:
Grant
Filed:
November 28, 2017
Date of Patent:
August 22, 2023
Assignee:
Sartorius BioAnalytical Instruments, Inc.
Abstract: The present invention relates to a method for diagnosis of delayed bone fracture healing, comprising determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+, CD8+CD28? and CD8+CD28?/CD57+, in a sample obtained from a subject. The present invention further relates to a system and a kit of parts for prediction and resulting options for preventing of delayed bone fracture healing.
Type:
Grant
Filed:
December 12, 2019
Date of Patent:
May 2, 2023
Assignee:
CHARITÉ UNIVERSITATSMEDIZIN BERLIN
Inventors:
Georg Duda, Hans-Dieter Volk, Simon Reinke, Christian Meisel, Christian Kleber, Sven Geissler, Katharina Schmidt-Bleek
Abstract: Methods, systems and kits for the early diagnosis or prediction of systemic inflammatory response syndrome (SIRS) including sepsis in asymptomatic patients, such as patients undergoing a surgical intervention, are provided. Some embodiments include a method and system for the detection or diagnosis of SIRS, or detection or diagnosis of a risk to suffer from or develop SIRS, in an asymptomatic patient comprising the steps of determining the level of IL-6 (or a variant thereof) in a sample from the patient; comparing the level of IL-6 (or a variant thereof) to a reference level; detecting or diagnosing SIRS or diagnosing a risk to suffer from or develop SIRS, wherein the sample is isolated at least 2 times at short intervals and the determining and comparing steps are both repeated for each sample. Also provided are methods, systems and kits for therapy monitoring and mortality prediction.
Abstract: The present invention provides an immunological binding partner reactive with a C-terminal epitope of the C5 domain of the ?3 chain of collagen Type 6, and a method of immunoassay using the immunological binding partner for detecting and quantifying the C-terminal epitope. The invention also provides a method of investigating the rate of formation of extracellular matrix and a method for identifying a subject suitable for treatment with an insulin sensitizer.
Type:
Grant
Filed:
June 5, 2019
Date of Patent:
April 25, 2023
Assignee:
Nordic Bioscience A/S
Inventors:
Anders Nedergaard, Jannie Marie Sand, Shu Sun, Diana Julie Oersnes-Leeming, Kim Henriksen
Abstract: A method for detecting and quantifying of the frequency of T cells to multiple antigenic peptide epitopes comprising: measuring intracellular Ca2+ signaling in individual T cells that are labeled with Ca2+ sensitive fluorophore; wherein said T cells are placed on the glass bottom of a well-covered with antibodies or other capturing proteins specific for non-stimulatory T cells' surface receptors and wherein a peptide antigens are injected into the well and the peptide binds to MHC molecules on the T-cell surface, wherein an increase in the intracellular concentration of Ca2+ in responding T cells leads to rise in intracellular fluorescence that is detected by fluorescent microscope and wherein the response rate of said detected fluorescence can be utilized to determine the quantity of responding T cells and the efficiency of said cells.
Abstract: The present invention provides for metallic structures comprising a sulfhydryl or amino-terminated hydrophilic coating to provide a layer of hydrophilic character on the surface of the metallic structures thereby allowing the use of low volumes of aqueous solvents of fluorophores that have the ability to “spread out” across the surfaces of the metallic structures and to provide for a more uniform surface coating of fluorophores attached to or near the metallic structures.
Type:
Grant
Filed:
July 22, 2016
Date of Patent:
January 24, 2023
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
Abstract: Herein is reported a method for the determination of the amount of a bivalent antibody in a serum or plasma sample obtained from a non-human experimental animal, whereby the antibody comprises one or more mutations in the Fc-region compared to the corresponding wild-type Fc-region that has a sequence of SEQ ID NO: 01, 02, or 03, wherein the method comprises the following steps a) immobilizing a non-antibody polypeptide to which more than one copy of the antigen of the antibody is covalently conjugated on a solid surface, b) incubating the immobilized antigen with the sample to form an immobilized antigen-antibody complex, c) incubating the immobilized antigen-antibody complex with the antigen conjugated to a detectable label to form an immobilized ternary complex, and d) determining the amount of the antibody by determining the amount of the detectable label in the immobilized ternary complex.
Abstract: A method is taught for the accurate determination of the premature rupture of membranes (PROM), defined as spontaneous rupture of membranes before the onset of uterine contractions. More specifically, a lateral flow assay strip tests for at least two antigens to greatly limit or eliminate the possibility of false negatives. A built-in timer in the cassette holding the lateral flow assay further increases the accuracy of the test. A collection buffer vial with self-contained shipping and dropper caps and built-in stand is also taught.
Abstract: Monoclonal and polyclonal antibodies that bind hamster phospholipase B-like 2 are provided. Also provided are methods for detecting and quantifying hamster phospholipase B-like 2, for example, in recombinant polypeptide preparations, as well as kits for carrying out such methods. Methods of screening or selecting host cell lines or recombinant polypeptide-expressing cell lines that express low levels of hamster phospholipase B-like 2 are also provided.
Type:
Grant
Filed:
March 7, 2018
Date of Patent:
December 6, 2022
Assignee:
Genentech, Inc.
Inventors:
Feny Gunawan, Yi-Chun Hsiao, Denise C. Krawitz, Margaret S. Lin, Martin Vanderlaan, Rajesh Vij, Inn H. Yuk, Judith Zhu-Shimoni
Abstract: The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
October 25, 2022
Assignees:
Universitet Maastricht, Academisch Ziekenhuis Maastricht
Inventors:
Harald Horst Heinz Wilhelm Schmidt, Mahmoud Hassan Mahmoud Elbatrik, Hermann Alois Martin Mucke
Abstract: Provided is a novel kit and assay for free and lipid-bound (exosomal) Hsp70. In particular, an ELISA is described for determining the level of Hsp70 in sample derived from a body fluid of a subject, characterized in that the level of Hsp70 is determined by an anti-Hsp70 antibody.
Abstract: The present invention relates to an in vitro method for diagnosing lupus in a subject, said method comprising the step of detecting in a biological sample obtained from the subject the autoantibody recognizing the protein biomarker THEX1. More, the invention relates to kits and array useful for carrying out diagnosis methods according to the present invention.
Type:
Grant
Filed:
February 7, 2019
Date of Patent:
October 4, 2022
Assignees:
INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, GFRS (Groupe Francophone de Recherche sur la Sclerodermie Systemique)
Inventors:
Nathalie Lambert, Fanny Arnoux, Doua Azzouz
Abstract: The present invention relates to method for detecting a free histone protein in a biological sample of a subject, e.g. using an immunoassay or a mass spectrometric assay. It also pertains to a method for the diagnosis, prognosis, risk assessment, risk stratification and/or therapy control of a disease or medical condition, comprising detecting a free histone protein or peptide fragment thereof in a biological sample of a subject, wherein the presence of said free histone protein or fragment thereof is indicative for said disease or medical condition.
Type:
Grant
Filed:
February 9, 2016
Date of Patent:
July 19, 2022
Assignee:
B.R.A.H.M.S. GMBH
Inventors:
Maryann Stephanie Vogelsang, Bryan Krastins, Anne Incamps, Andre Schoenichen, Tim Ziera